Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Overview 6 Therapeutics Development 7 Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Products under Development by Stage of Development 7 Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Products under Development by Therapy Area 8 Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Products under Development by Indication 9 Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Products under Development by Companies 12 Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Products under Development by Universities/Institutes 14 Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 19 Assessment by Molecule Type 20 Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Companies Involved in Therapeutics Development 21 Nippon Kayaku Co., Ltd. 21 Shenogen Pharma Group Ltd. 22 Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Drug Profiles 23 CB-7993113 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 CDR-914K058 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 cinnabarinic acid - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 ITE - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 NK-150460 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 SNG-162 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Dormant Projects 30 Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Featured News & Press Releases 31 Nov 02, 2015: Hercules Receives €3.5 Million EUROSTARS Grant for Further Development of a New Drug for Triple Negative Breast Cancer 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 32 Disclaimer 33

List of Tables Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Assessment by Monotherapy/Combination Products, H2 2016 16 Number of Products by Stage and Mechanism of Action, H2 2016 18 Number of Products by Stage and Route of Administration, H2 2016 19 Number of Products by Stage and Molecule Type, H2 2016 20 Pipeline by Nippon Kayaku Co., Ltd., H2 2016 21 Pipeline by Shenogen Pharma Group Ltd., H2 2016 22 Dormant Projects, H2 2016 30 List of Figures Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Top 10 Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 11 Assessment by Monotherapy/Combination Products, H2 2016 16 Number of Products by Mechanism of Actions, H2 2016 17 Number of Products by Stage and Mechanism of Actions, H2 2016 17 Number of Products by Stage and Routes of Administration, H2 2016 19 Number of Products by Stage and Molecule Type, H2 2016 20

Nippon Kayaku Co., Ltd. Shenogen Pharma Group Ltd.